Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Faculty of Medicine, Oita University | Japan

Author Profile 

Scopus

🧬 Dr. Haruto Nishida, M.D., Ph.D. – Associate Professor of Diagnostic Pathology

Haruto Nishida, M.D., Ph.D., is an Associate Professor at the Department of Diagnostic Pathology at Oita University Hospital, Japan, where he has served in this role since April 2021. Dr. Nishida has a profound expertise in pathology, with a particular focus on diagnostic pathology, cytology, and molecular pathology.

🎓 Education and Early Career

Dr. Nishida earned his Medical Degree from the Faculty of Medicine at Oita University in 2009. He furthered his academic journey by obtaining a Ph.D. from the same institution in 2015, specializing in pathology. His post-graduate training includes a residency in General Medicine at Oita Medical Hospital and a fellowship in Diagnostic Pathology at Oita University.

đź©ş Professional Experience

Dr. Nishida’s career at Oita University has been marked by progressive roles. Starting as an Assistant Professor in 2012, he was promoted to Lecturer in 2019 and then to Associate Professor in 2020. He continued in this role when he transitioned to Oita University Hospital in 2021, where he currently leads efforts in diagnostic pathology.

🏅 Board Certifications and Licensure

Dr. Nishida holds multiple prestigious board certifications, including the Japanese Board Certification in Pathology, Autopsy, Cytology, and Molecular Pathology. He earned his National Board of Medicine license in 2009, showcasing his dedication to the field.

🌍 Professional Affiliations

Dr. Nishida is an active member of several professional organizations, both in Japan and internationally. He is involved with the Japanese Society of Pathology, Japanese Society of Clinical Cytology, Japan Dermatopathology Society, and the Bone and Soft Tissue Tumor Club of Japan. Additionally, he is a member of the United States and Canadian Academy of Pathology (USCAP) and the International Academy of Cytology.

Dr. Nishida’s contributions to the field of pathology, combined with his ongoing research and teaching, make him a distinguished figure in diagnostic pathology.

🚀 Conclusion

In summary, Dr. Haruto Nishida is a highly accomplished pathologist whose extensive expertise and dedication to diagnostic pathology have significantly contributed to the field. His career, marked by a progression of academic and clinical roles at Oita University, is underpinned by his strong educational background and numerous board certifications. As an active member of both national and international professional organizations, Dr. Nishida continues to impact the field through his research, teaching, and clinical work. His ongoing commitment to excellence in pathology makes him a respected leader in the medical community.

 

📊🔬NOTABLE PUBLICATION:

 

  • SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 Fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors
    Authors: Macagno, N., Kervarrec, T., Thanguturi, S., De la Fouchardière, A., Battistella, M.
    Journal: Modern Pathology
    Year: 2024

 

  • Recurrent Cardiac Tamponade Following Coronavirus Disease 2019 mRNA Vaccination: A Case Report
    Authors: Kaimori, R., Nishida, H., Yahiro, T., Iwami, T., Daa, T.
  • Journal: Cardiovascular Pathology
    Year: 2024

 

  • Lipid Droplet Detection in Histopathological Images Using Reinforcement Learning
    Authors: Harada, Y., Nishida, H., Matsuura, K.
    Journal: Biotechnology and Biotechnological Equipment
    Year: 2024

 

  • Right Atrial Cardiac Myxoma with Malignant Transformation to Undifferentiated Sarcoma: A Case Report
    Authors: Kaimori, R., Nishida, H., Oyama, Y., Kawamura, K., Daa, T.
    Journal: Cardiovascular Pathology
    Year: 2024

 

  • The Relationship Between Tumor Immunity and the cGAS–STING Pathway in Breast Cancer: An Immunohistochemical Study
    Authors: Nishida, H., Ohara, N., Kato, A., Kawamura, K., Daa, T.
    Journal: Experimental and Molecular Pathology
    Year: 2024

Ms. Hao Li – Tumor Immunology – Young Scientist Award

Ms. Hao Li - Tumor Immunology - Young Scientist Award

First Hospital of China Medical University - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Li Hao began his academic journey at Dalian Medical University in September 2015, majoring in Immunology, Biochemistry, Surgery, and Internal Medicine. During this period from 2015 to 2020, he laid the foundational knowledge in the medical sciences that would serve as the basis for his future specialization. His undergraduate studies provided him with a comprehensive understanding of the human body's immune system, biochemistry, surgical techniques, and internal medicine.Li Hao pursued his Master's degree in Emergency Medicine and Molecular Biology at China Medical University. This advanced academic pursuit enabled him to delve deeper into specialized areas of medicine, focusing on emergency care and the molecular mechanisms underlying various medical conditions.

PROFESSIONAL ENDEAVORS

In May 2021, Li Hao started his professional career as a Resident Physician at the First Hospital of China Medical University. During his tenure from May 2021 to August 2021, he gained hands-on experience in clinical settings, honing his skills in medical records writing and cardiopulmonary resuscitation (CPR). This role allowed him to apply his theoretical knowledge from his undergraduate studies in a practical setting, preparing him for more specialized roles in the medical field.In June 2023, Li Hao transitioned to the role of an Assistant at the First Hospital of China Medical University, where he continues to work to the present day. As an Assistant, he has been involved in research projects and clinical work, further expanding his expertise and contributing to advancements in the medical field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Li Hao's research interests are diverse and interdisciplinary, focusing on the areas of nanomaterials, hepatocellular carcinoma, and macrophage biology. His research aims to explore innovative approaches and treatments for these medical conditions, leveraging the latest advancements in molecular biology and emergency medicine.

IMPACT AND INFLUENCE

Li Hao's contributions to the medical field extend beyond his professional roles, as he actively engages in research and academic pursuits that have the potential to make a significant impact. His research in nanomaterials, hepatocellular carcinoma, and macrophage biology could lead to breakthroughs in treatment options and improve patient outcomes in these areas.

ACADEMIC SITES

Li Hao's academic achievements and research contributions have likely been cited in various scientific publications and conferences. His interdisciplinary research in nanomaterials, hepatocellular carcinoma, and macrophage biology demonstrates his commitment to advancing medical science and contributing valuable insights to the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Li Hao continues to pursue his career in emergency medicine and molecular biology, his interdisciplinary research and clinical experience will undoubtedly leave a lasting legacy in the medical field. His dedication to improving patient care and advancing medical science positions him as a promising young professional with the potential to make significant contributions to the future of healthcare.

NOTABLE PUBLICATIONS

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.  2024

Glutamate Chemical Exchange Saturation Transfer (GluCEST) MRI to Evaluate the Rapid Antidepressant Effects of Ketamine in the Hippocampus of Rat Depression Model. 2024 (1)

Preclinical multi-physiologic monitoring of immediate-early responses to diverse treatment strategies in breast cancer by optoacoustic imaging. 2024

Glutamate alterations in the premature infant brain during different gestational ages with glutamate chemical exchange saturation transfer imaging: a pilot study. 2023 (1)

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups. 2023 (1)